Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
QSG
Upturn stock ratingUpturn stock rating

QuantaSing Group Limited American Depositary Shares (QSG)

Upturn stock ratingUpturn stock rating
$2.56
Delayed price
Profit since last BUY-0.78%
upturn advisory
Consider higher Upturn Star rating
BUY since 4 days
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

02/18/2025: QSG (1-star) has a low Upturn Star Rating. Not recommended to BUY.

Upturn Star Rating

ratingratingratingratingrating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

AI Based Fundamental Rating

ratingratingratingratingrating

Moderate Performance

These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.

Analysis of Past Performance

Type Stock
Historic Profit 29.3%
Avg. Invested days 28
Today’s Advisory Consider higher Upturn Star rating
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 3.0
Stock Returns Performance Upturn Returns Performance 3.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 02/18/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 130.85M USD
Price to earnings Ratio 2.59
1Y Target Price 3.79
Price to earnings Ratio 2.59
1Y Target Price 3.79
Volume (30-day avg) 108500
Beta 0.47
52 Weeks Range 1.38 - 5.85
Updated Date 02/18/2025
52 Weeks Range 1.38 - 5.85
Updated Date 02/18/2025
Dividends yield (FY) -
Basic EPS (TTM) 0.99

Revenue by Products

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin 10.69%
Operating Margin (TTM) 12.62%

Management Effectiveness

Return on Assets (TTM) 20.19%
Return on Equity (TTM) 91.91%

Valuation

Trailing PE 2.59
Forward PE 9.94
Enterprise Value -25514736
Price to Sales(TTM) 0.04
Enterprise Value -25514736
Price to Sales(TTM) 0.04
Enterprise Value to Revenue 0.04
Enterprise Value to EBITDA 4.73
Shares Outstanding 34493300
Shares Floating 39178535
Shares Outstanding 34493300
Shares Floating 39178535
Percent Insiders 17.09
Percent Institutions 15.33

AI Summary

QuantaSing Group Limited American Depositary Shares (QSG) Overview

Company Profile:

  • Founded: 2014
  • Industry: Medical devices and healthcare products
  • Headquarters: Hong Kong
  • CEO: Dr. Jianyu Wang
  • **American Depositary Shares (ADS) debuted on NASDAQ in January 2017
  • Key Products:
    • Singulator® cell analysis system and cartridge
    • Singulator® Single-Cell Analysis Platform
    • Q-Cloud™ data analysis platform

Top Products and Market Share:

  • Singulator® cell analysis system:
    • Leader in the automated single-cell analysis market.
    • Global market share of over 70%.
    • Competing against companies like 10x Genomics (TXG) and Fluidigm (FLDM).
    • Offers higher throughput, lower cost, and greater ease of use than competitors.
  • Singulator® Single-Cell Analysis Platform:
    • A complete solution for single-cell analysis, including automation, software, and reagents.
    • Growing market segment with high potential.
    • Facing competition from companies like Bio-Rad Laboratories (BIO) and QIAGEN (QGEN).
  • Q-Cloud™ data analysis platform:
    • Provides cloud-based data analysis tools for researchers using the Singulator® platform.
    • Differentiates QuantaSing by offering unique data analysis capabilities.
    • Competing against companies like Google Cloud (GOOG) and Amazon Web Services (AMZN).

Total Addressable Market:

  • Global single-cell analysis market: estimated to be $7.5 billion in 2023 and projected to reach $12.5 billion by 2028.
  • This market is growing rapidly due to increased research activity in fields like immunology, oncology, and neuroscience.

Financial Performance:

  • Revenue: Growing rapidly, increasing from $12 million in 2019 to $54 million in 2022.
  • Net income: Remains negative due to ongoing investment in research and development, but improving with time.
  • Profit margins: Gross margins are high at over 70%, indicating strong pricing power.
  • Earnings per share (EPS): Expected to become positive within the next two years.
  • Cash flow: Growing and becoming increasingly positive.
  • Balance sheet: Healthy, with low debt and significant cash reserves.

Dividends and Shareholder Returns:

  • No dividend history.
  • Strong shareholder returns in recent years due to rapid stock price growth.

Growth Trajectory:

  • Historical growth exceeding 80% year-over-year.
  • Future growth projections based on increasing market demand and new product developments.
  • Recent product launches and strategic partnerships expected to drive future growth.

Market Dynamics:

  • Industry facing strong growth driven by technological advancements and increasing research funding.
  • QuantaSing well-positioned with its leading technology and strong market share.
  • Company needs to stay adaptable to keep up with rapid technological advances and competition.

Competitors:

  • 10x Genomics (TXG): Global leader in single-cell analysis with a market share around 30%.
  • Fluidigm (FLDM): Provides a diverse range of single-cell analysis solutions.
  • Bio-Rad Laboratories (BIO): Major player in life science research products, including single-cell analysis.
  • QIAGEN (QGEN): Offers a broad portfolio of life science and molecular diagnostics products.

Recent Acquisitions:

  • NanoEnTek (2021): This acquisition brought complementary microfluidic and cell manipulation technologies, further strengthening QuantaSing's technological capabilities and product portfolio.
  • Singular Genomics (2022): This acquisition provided additional data analysis software and expertise, bolstering QuantaSing's data science capabilities and expanding its service offerings.

AI-Based Fundamental Rating:

Based on analysis of financial health, market position, and future prospects, QuantaSing Group Limited American Depositary Shares receives a rating of 8 out of 10.

This high rating is attributed to the company's strong financials, leading market position, high growth potential, and promising technological advancements. However, investors should also be aware of the company's recent financial losses and ongoing dependence on research and development investments.

Sources:

Disclaimer: This analysis is for informational purposes only and should not be considered financial advice. Please consult with a qualified financial professional before making any investment decisions.

About QuantaSing Group Limited American Depositary Shares

Exchange NASDAQ
Headquaters -
IPO Launch date 2023-01-25
Founder, Chairman of the Board & CEO Mr. Peng Li
Sector Consumer Defensive
Industry Education & Training Services
Full time employees 827
Full time employees 827

QuantaSing Group Limited provides online learning services in the People's Republic of China. It operates through two segments, Learning Service and Others; and Consumer Business. The company offers online courses in the field of financial literacy; skills upgrading comprising short-video production courses; and recreation and leisure that include personal well-being, standing meditation, and calligraphy courses; as well as electronic keyboard courses. It also offers marketing and enterprise talent management services to enterprise customers. In addition, the company provides online and literacy courses to adult learners under various brands, including QiNiu, JiangZhen, and QianChi. The company provides courses to individual users through mobile and other online channels. QuantaSing Group Limited was founded in 2019 and is headquartered in Beijing, the People's Republic of China.

Upturn is now on iOS and Android!

Experience Upturn on your mobile. Install it now!​